Show simple item record

dc.contributor.authorMaxan, Alexander
dc.contributor.authorMason, Sarah
dc.contributor.authorSaint-Pierre, Martine
dc.contributor.authorSmith, Emma
dc.contributor.authorHo, Aileen
dc.contributor.authorHarrower, Timothy
dc.contributor.authorWatts, Colin
dc.contributor.authorTai, Yen
dc.contributor.authorPavese, Nicola
dc.contributor.authorSavage, Julie C
dc.contributor.authorTremblay, Marie-Ève
dc.contributor.authorGould, Peter
dc.contributor.authorRosser, Anne E
dc.contributor.authorDunnett, Stephen B
dc.contributor.authorPiccini, Paola
dc.contributor.authorBarker, Roger A
dc.contributor.authorCicchetti, Francesca
dc.date.accessioned2018-11-22T00:32:23Z
dc.date.available2018-11-22T00:32:23Z
dc.date.issued2018-12
dc.identifier.issn0364-5134
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/285658
dc.description.abstractFor patients with incurable neurodegenerative disorders such as Huntington's (HD) and Parkinson's disease, cell transplantation has been explored as a potential treatment option. Here, we present the first clinicopathological study of a patient with HD in receipt of cell-suspension striatal allografts who took part in the NEST-UK multicenter clinical transplantation trial. Using various immunohistochemical techniques, we found a discrepancy in the survival of grafted projection neurons with respect to grafted interneurons as well as major ongoing inflammatory and immune responses to the grafted tissue with evidence of mutant huntingtin aggregates within the transplant area. Our results indicate that grafts can survive more than a decade post-transplantation, but show compromised survival with inflammation and mutant protein being observed within the transplant site. Ann Neurol 2018;84:950-956.
dc.description.sponsorshipThe trial was supported by a grant from the MRC and the follow up by NIHR funding of a Biomedical Research Centre in Cambridge to the Addenbrooke’s Hospital and University of Cambridge. AM is supported by the Fonds de Recherche du Québec en santé (FRQS) and the O’Brien Foundation. FC is a recipient of a Researcher Chair from FRQS providing salary support and operating funds, and receives funding from the Canadian Institutes of Health Research (CIHR) to conduct her HD-related research. RAB and SLM are supported by a grant from the MRC. RAB is a PI at the Wellcome Trust-MRC funded Cambridge Stem Cell Institute and an NIHR Senior Investigator.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherWiley
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBrain
dc.subjectMicroglia
dc.subjectInterneurons
dc.subjectHumans
dc.subjectHuntington Disease
dc.subjectAcetylcholinesterase
dc.subjectParvalbumins
dc.subjectNerve Tissue Proteins
dc.subjectAntigens, CD
dc.subjectBrain Tissue Transplantation
dc.subjectAdult
dc.subjectMale
dc.subjectCalbindin 2
dc.subjectAllografts
dc.subjectHuntingtin Protein
dc.titleOutcome of cell suspension allografts in a patient with Huntington's disease.
dc.typeArticle
prism.endingPage956
prism.issueIdentifier6
prism.publicationDate2018
prism.publicationNameAnn Neurol
prism.startingPage950
prism.volume84
dc.identifier.doi10.17863/CAM.33010
dcterms.dateAccepted2018-09-27
rioxxterms.versionofrecord10.1002/ana.25354
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-12
dc.contributor.orcidMason, Sarah [0000-0001-6715-4109]
dc.contributor.orcidBarker, Roger [0000-0001-8843-7730]
dc.identifier.eissn1531-8249
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (146281)
pubs.funder-project-idMedical Research Council (MC_PC_12009)
cam.issuedOnline2018-10-25


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International